Protein phosphatase 2A (PP2A) consists of three subunits, A, B and C. The A and B subunits have regulatory functions while C is the catalytic subunit. PP2A core enzyme is composed of subunits A and C, and the holoenzyme of subunits A, B and C. All subunits exist as multiple isoforms or splice variants. The A subunit exists as two isoforms, Aa and Ab. Here we report about the properties of eight Ab mutants, which were found in human lung and colon cancer. These mutants were reconstructed by site-directed mutagenesis and assayed for their ability to bind B and C subunits. Two mutants showed decreased binding of PR72, a member of the B'' family of B subunits, but normal C subunit binding; two mutants exhibited decreased binding of the C subunit and of B''/PR72; and one mutant showed increased binding of both the C subunit and B''/PR72. Of three mutants that behaved like the wildtype Ab subunit, one is a polymorphic variant and another one is altered outside the binding region for B and C subunits. Importantly, we also found that the wildtype Aa and Ab isoforms, although 85% identical, are remarkably dierent in their ability to bind B and C subunits. Our ®ndings may have important implications in regard to the role of PP2A as a tumor suppressor.
Introduction
It has been suggested that the serine/threonine-speci®c protein phosphatase 2A (PP2A) might be a tumor suppressor (Cohen and Cohen, 1989 ) based on the ®nding that okadaic acid is both a strong inhibitor of PP2A (Bialojan and Takai, 1988 ) and a potent tumor promoter (Suganuma et al., 1988) . Direct evidence for this suggestion has been lacking until recently, when Wang et al. (1998) discovered that the gene encoding the b isoform of the A subunit of PP2A was altered in 15% of primary lung tumors (small-cell and non-smallcell lung carcinomas), in 6% of lung tumor-derived cell lines, and in 15% of primary colon tumors. Furthermore, Takagi et al. (2000) described mutations in the Ab subunit gene in four colon cancer cases. In addition, Calin et al. (2000) reported that both the Aa and Ab subunit isoforms of PP2A are genetically altered in a variety of primary human cancers.
PP2A is composed of three subunits, A, B and C. The core enzyme consists of a 36-kDa catalytic C subunit and a 65-kDa regulatory A subunit. One of several regulatory B subunits can bind to the core enzyme, and the heterotrimer composed of the A, B and C subunits is called holoenzyme (Mumby and Walter, 1993, for review) . The A subunit exists as two isoforms (a and b) (Hemmings et al., 1990; Walter et al., 1989) as does the C subunit (da Cruz e Silva et al., 1987; Green et al., 1987; Kitagawa et al., 1988; Stone et al., 1987) , whereas the B subunits fall into three families designated B, B' (also called B56), and B''. The B family has four members, Ba, Bb, Bg and Bd, each with a molecular mass of around 55 kDa (Healy et al., 1991; Mayer et al., 1991; Pallas et al., 1992; Strack et al., 1999; Zolnierowicz et al., 1994) . The B' family consists of numerous isoforms and splice variants whose molecular masses range from 54 to 68 kDa (Csortos et al., 1996; McCright et al., 1996; McCright and Virshup, 1995; Tanabe et al., 1996; Tehrani et al., 1996) . The B'' family has at least four members, designated PR48 (Yan et al., 2000) , PR59 (Voorhoeve et al., 1999) , and PR72/PR130 (Hendrix et al., 1993; Nagase et al., 1997) . PR72 and PR130 are splice variants of the same gene (Hendrix et al., 1993) . The B subunits determine substrate speci®city and subcellular localization (Cegielska et al., 1994; McCright et al., 1996; Tehrani et al., 1996) . In addition, some B subunits are expressed in a tissues-speci®c fashion and at distinct developmental stages (Csortos et al., 1996; McCright et al., 1996., McCright and Virshup, 1995; Tehrani et al., 1996) . Tumor (T) antigens encoded by polyoma viruses, which play key roles in neoplastic transformation, represent a fourth class of proteins able to associate with the PP2A core enzyme (Mumby, 1995; Walter and Mumby, 1993, for review) . Another viral protein that interacts with PP2A is adenovirus E4orf4. By binding the B subunit in the holoenzyme, E4orf4 induces p53-independent apoptosis (Kleinberger and Shenk, 1993; Marcellus et al., 2000; Shtrichman et al., 1999 Shtrichman et al., , 2000 . PP2A also associates with numerous cellular proteins that are involved in growth regulation Virshup, 2000) . They include several protein kinases (Abraham et al., 2000; Heriche et al., 1997; Lebrin et al., 1999; Westphal et al., 1998 Westphal et al., , 1999 , the Rb-related protein p107 (Voorhoeve et al., 1999) , heat shock protein HSF2 (Hong et al., 2000) , adenomatous polyposis coli (APC) protein (Seeling et al., 1999) , axin (Hsu et al., 1999) , translation termination factor eRF1 (Andjelkovic et al., 1996) , HOX 11 (Kawabe et al., 1997) , myeloid leukemia-associated protein SET (Li et al., 1996) , caspase 3 (Santoro et al., 1998) , and Bc12 (Deng et al., 1998) .
The interaction between the A, B and C subunits in the core and holoenzymes and between the core enzyme and T antigens is illustrated in a model shown in Figure 1 (Ruediger et al., 1992 (Ruediger et al., , 1994 . The Aa subunit polypeptide consists of 15 nonidentical repeats (Hemmings et al., 1990; Walter et al., 1989) . Each repeat is composed of two a helices connected by a loop (intra-repeat loop). Adjacent repeats are connected by inter-repeat loops. Collectively, the repeats form an extended molecule (Chen et al., 1989) that is largely stabilized by hydrophobic interactions (Ruediger et al., 1994) . This model for the Aa subunit was con®rmed and extended by the X-ray structure (Groves et al., 1999) . We have shown that intra-repeat loops are involved in binding B and C subunits as well as T antigens. The B subunits bind to repeats 1 ± 10, and the C subunit binds to repeats 11 ± 15 of the Aa subunit (Kremmer et al., 1997; Ruediger et al., 1992 Ruediger et al., , 1994 .
Elucidating how cancer-associated mutations in the Aa and Ab subunit genes alter the properties of PP2A is a key to understanding the role of PP2A in growth control and carcinogenesis. In a recent study, we demonstrated that four mutations in the Aa subunit gene, which were found in human cancer (Calin et al., 2000) , render the Aa subunit defective in interacting with B or B and C subunits (Ruediger et al., 2001) . These results suggest that mutations in Aa play a role in tumor development. In the present report, we show that mutants of the Ab isoform found in colon and lung cancer are defective in interacting with B and C subunits. Our studies also demonstrate that B and C subunits bind to N-and C-terminal domains, respectively, of the Ab isoform, as described for the Aa isoform. However, Aa and Ab, although highly homologous, show profound dierences in their capacity to bind B and C subunits.
Results

Generation of Ab subunit mutants
The colon and lung cancer-associated mutations in the Ab subunit that were investigated are shown in Figure  2 . Based on location and potential interactions with B and C subunits, they can be subdivided into two groups. One group consists of mutations located in the N-terminal domain (repeats 1 ± 10) involved in binding B subunits. The other group consists of mutations located in the C-terminal domain (repeats 11 ± 15) responsible for binding C subunits. This classi®cation is based on the assumption that the Ab subunit, because of its high degree of homology to Aa, has the same overall structure and the same location of B and C subunit binding domains as the Aa subunit (Figure 1 ). Most cancer-associated Ab mutants contain one missense mutation resulting in a single amino acid exchange, except for mutant L101P/V448A, which contains two missense mutations, one (L101P) in the B subunit binding domain (repeat 3) and one (V448A) in the C subunit binding domain (repeat 12). One mutant has a deletion of 45 amino acids spanning parts of repeats 9 and 10. We generated these mutants by site-directed mutagenesis and added the EE tag (EEEEYMPME) to the C terminus. We also generated the L101P and V448A single mutants for comparison with the double mutant.
B and C subunit binding assays
The ability of Ab subunits to form complexes with Ba (Kamibayashi et al., 1994) , B'a1 (Tehrani et al., 1996) , and B''/PR72 (Hendrix et al., 1993) was assayed by incubating in vitro synthesized, radiolabeled Ab with in vitro synthesized, radiolabeled B subunits. The C subunit required for complex formation was supplied in unlabeled form as an endogenous component of the reticulocyte lysate. The complexes were immunoprecipitated with antibodies against the EE tag and analysed by SDS ± PAGE. The ability of Ab to form complexes with the C subunit was assayed by incubating radiolabeled, in vitro synthesized Ab in the reticulocyte lysate in order to allow binding to endogenous (unlabeled) C subunit. The complexes were then immunoprecipitated with antibodies against the KL peptide (KVTRRTPDYFL), corresponding to the C terminus of the C subunit, and analysed for coimmunoprecipitated, radiolabeled Ab subunit.
Reduced ability of wild-type Ab to bind B and C subunits
As mentioned above, we expected that the Aa and Ab subunits would reveal similar B and C subunit binding Table 1 . Mutant D1-4-Aa EE , which does not bind B subunits, was used as a negative control for background binding. This background was subtracted from all values for the purpose of quanti®cation. The higher background for B'a1 as compared to Ba indicates that B'a1 is stickier than Ba. It should be emphasized that a considerable eort was made to ensure that the Ab construct used for the binding and mutagenesis experiments is a true wild-type (see Materials and methods), because a single point mutation could dramatically change the B or C subunit binding properties, as demonstrated in the present report and in previous studies with Aa (Ruediger et al., 1999 (Ruediger et al., , 2001 ).
Altered binding of B''/PR72 and C subunits to mutants of Ab
Since the wild-type Ab subunit did not bind Ba and B'a1, Ab mutants were not assayed for Ba and B'a1 binding, but only for binding B''/PR72 and C subunits. Four types of mutants could be distinguished. The ®rst group, consisting of mutants P65S, L101P, and DE344-E388, shows reduced B''/PR72 subunit binding as compared to wild-type Ab (Figure 4 , lanes 5, 12, 9), whereas C subunit binding is normal (Figure 5, lanes 7, 8, 21, 22, 15, 16) . The second group is characterized by reduction in both B''/PR72 and C subunit binding. Mutants V448A, L101P/V448A and V545A belong to this category (Figure 4, lanes 13, 7, 11; Figure 5, lanes 23, 24, 11, 12, 19, 20) . It is likely that the reduced binding of B''/PR72 in this group is the result of defective C subunit binding, in analogy to the Aa subunit, which binds B subunits only in the presence of a C subunit (Kamibayashi et al., 1992 (Kamibayashi et al., , 1994 Ruediger et al., 1992 Ruediger et al., , 1994 . It is noteworthy that the tumorassociated double mutant, L101P/V448A, is more defective in binding B and C subunits than either one of the corresponding single mutants, indicating that the defects of the single mutants are additive (Figure 2) . Third, one mutant, D504G, has the unexpected property of strongly increased C and B''/PR72 binding ( Figure 4 , lane 10; Figure 5 , lanes 17, 18). The increased B''/PR72 binding is likely to be a consequence of increased C subunit binding. Finally, three mutants (G8R, G90D and K343E) are normal in B''/ Shown are seven repeats of the Ab subunit (numbered to the left), the a helices A and B, and the intra-repeat loops (underlined by dotted lines), as suggested by the X-ray structure of the Aa subunit (Groves et al., 1999) . Mutants are named at their respective positions in Ab. Their binding to B''/PR72 and C is expressed as per cent of wild-type Ab subunit binding, with standard deviations as indicated. The values are the average from three experiments for B''/PR72 and two experiments for C subunit binding. Note that mutants L101P and V448A were not found in cancer. They were generated for the purpose of comparison with the double mutant L101P/V448A 
Discussion
The key question raised by the discovery of mutations in the Aa and Ab genes in human cancer is whether these mutations are relevant for the tumorigenic process. Our previous discovery that all mutations in Aa are defective in binding either B or B and C subunits, together with the present ®nding that most mutations in Ab are defective in binding B''/PR72, or C and B''/PR72, strongly support the idea that PP2A plays a major role in tumorigenesis. We analysed eight mutants of the Ab subunit, six of which were found in lung carcinoma and two in colon carcinoma. The binding studies were carried out using an in vitro binding assay that faithfully re¯ects in vivo binding as demonstrated for several mutants in dierent systems, including the yeast two-hybrid system (McCright and Virshup, 1995) , mammalian cells in tissue culture (Ruediger et al., 1997) , and mice (Brewis et al., 2000) . Two N-terminal mutants (P65S and DE344 ± E388) showed strongly decreased B''/PR72 binding, while two C-terminal mutants (V448A and V545A) showed strongly decreased B''/PR72 and C binding consistent with the previous ®nding that B subunits cooperate with the C subunit in binding to the A subunit. A common feature of all four mutant proteins is their reduced capacity to form AbCB''/PR72 holoenzyme. One role of B''/PR72 may be to target the enzyme to a speci®c location in the nucleus, consistent with the ®nding that B''/PR72 contains a nuclear localization signal (Hendrix et al., 1993) . The ®nding that one mutant (D504G) bound signi®cantly more C and B''/PR72 than the wild-type Ab, resulting in increased formation of AbCB''/PR72, may indicate It is an open question whether and how three mutants, which had no measurable defect in C or B''/PR72 binding, could have an eect on growth. One of them (G8R) may not be defective in B''/PR72 binding because the mutation is located within a region of 12 amino acids at the N terminus that is unique to Ab and may not be required for B''/PR72 subunit binding. Instead, this region might be involved in binding an unknown protein, which is unrelated to B subunits but involved in growth control. The G8R mutation might abrogate binding of this protein. The second mutant (G90D) which behaved like the wild-type protein is likely to represent a polymorphic variant since it was present in normal tissue (Campbell and Manolitsas, 1999) . The third mutant (K343E) could also be a polymorphic variant although there is presently no evidence for this suggestion.
It is important to point out that the mutations D504G and V545A are located in the intra-repeat loops of repeats 13 and 14, respectively (Figure 2) , which are involved in C subunit binding according to our model of the Aa subunit ( Figure 1 ). As deduced from the X-ray structure of the Aa subunit, the carboxyl group of the Asp 504 side chain forms a hydrogen bond with His 509, stabilizing the conformation of the intra-repeat loop. The reason why the mutation of Asp 504 to Gly enhances C subunit binding rather than inhibiting it is not apparent from the X-ray structure. Nevertheless, our ®nding is consistent with the notion that this intra-repeat loop is directly involved in C subunit binding. Val 545 is exposed as part of intra-repeat loop 14 and may strengthen the hydrophobic interaction with the C subunit (Groves et al., 1999) . The V448A mutation, which strongly reduces C subunit binding, is not located in an intra-repeat loop but at the beginning of helix A of repeat 12. By analogy with the Aa subunit X-ray structure, Val 448 interacts with Phe 485 at the end of helix B of repeat 12 and Trp 489 at the beginning of helix A of repeat 13, thereby stabilizing helix ± helix interactions. Mutation of Val 448 to Ala may cause an altered inter-helix conformation and indirectly reduce C subunit binding. The reduction in B''/PR72 binding by mutations P65S and L101P may also be caused by indirect eects on helix structure rather than a direct eect on binding. Pro 65 is highly conserved in most repeats and causes a bend within the A helix that stabilizes inter-helix hydrophobic interactions. Mutation of Pro 65 to Ser would probably eliminate the bend and destabilize the protein structure. Leu 101 is located in an unexposed helical position, which is occupied by a hydrophobic residue in all 15 A helices (Groves et al., 1999; Ruediger et al., 1994) . It is likely to be involved in hydrophobic helix ± helix interactions that are disrupted by mutation to Pro.
The discovery that the Ab subunit is mutated in human cancer (Wang et al., 1998) has, for the ®rst time, drawn attention to this isoform. Until then, the main focus was on the Aa subunit, and all biochemical studies of PP2A have been carried out with enzyme preparations containing the Aa subunit. The main reason for this neglect of Ab is that it is 40 times less abundant than Aa (Hemmings et al., 1990) , which is highly abundant, representing 0.1% of total cell protein (Ruediger et al., 1991) . Nevertheless, Ab falls within the concentration range of growth-regulatory proteins such as c-Src, c-Jun and p53. Based on the high degree of homology between the Aa and Ab subunits (85% identity), we expected that their structures and biochemical properties would be very similar. Indeed, the Ab subunit shares the general locations of B and C subunit binding regions described for Aa (Ruediger et al., 1992 (Ruediger et al., , 1994 , as suggested by the ®nding presented here that binding of B''/PR72 to Ab is strongly reduced by N-terminal mutations (P65S, L101P and DE344-E388), whereas binding of the C subunit is normal or only weakly aected. On the other hand, C subunit binding to Ab is strongly reduced by C-terminal mutations (V448A and V545A). But we also discovered signi®cant qualitative and quantitative dierences in the binding of B and C subunits. The ®nding that Ab binds neither Ba nor B'a1, and binds B''/PR72 threefold less than Aa, suggests that Aa and Ab have dierent functions and play dierent roles in growth control. It also implies that the mutations in Aa and Ab which were found in various human carcinomas contribute in dierent ways to the loss of growth control during tumorigenesis. Whereas Ab subunit mutations seem to aect processes involving the B''/PR72-containing holoenzyme (AbCB''/PR72), Aa subunit mutations may interfere with pathways in which B'-containing holenzymes (AaCB') play a major role (Ruediger et al., 2001; Seeling et al., 1999) . We and others have shown previously that the binding of B subunits to Aa depends on the presence of the C subunit. It is unknown whether the type of C subunit (a or b) determines which of the B subunits bind to Aa and Ab or how strong they bind. In theory, four forms of core enzyme are possible, AaCa, AaCb, AbCa and AbCb, and presently we do not know whether they all exist. In the assay used for measuring C subunit binding to Aa and Ab, the participating C subunit was supplied by the reticulocyte lysate. Since Ca is generally much more abundant than Cb, we assume that our assay measured predominantly binding of Ca to Aa and Ab, and, furthermore, that the measurement of B subunit binding re¯ects binding to AaCa and AbCa. However, it has not been excluded that a small amount of AbCb exists in reticulocyte lysate, which may bind Ba and B'a1. At present, we cannot test this possibility because the peptide antibody used for immunoprecipitation recognizes both Ca and Cb. Because of their high similarity (97% identity), it will be very dicult to generate antibodies that discriminate between the two forms. It seems likely, however, that Ca and Cb play dierent roles during mouse development (GoÈ tz et al., 1998) , suggesting that they interact dierently with regulatory subunits. Therefore, the investigation of Cb-containing forms of PP2A remains an important goal for the future.
It has been argued that the cancer-associated deletions in Ab may be artifacts resulting from the use of RT ± PCR for amplifying tumor RNA containing aberrantly spliced transcripts (Campbell and Manolitsas, 1999) . However, in regard to the deletion mutant DE344-E388, which has been found independently by two groups in six dierent primary tumors (four breast and two lung carcinomas), splicing artifacts have been excluded for the following reasons. First, Calin et al. (2000) demonstrated that the DNA encoding amino acids 344-388 (exon 9) was homozygously deleted from genomic DNA in tumor but not in matched normal tissue. Second, Wang et al. (1998) found a mutation inside intron 8 that could have caused loss of exon 9 due to a splicing error in tumor but not normal tissue. The question has been raised whether the point mutations seen in Ab may be a byproduct rather than a cause of cancer development, due to the fact that mutation rates are generally increased in cancer (Campbell and Manolitsas, 1999; Gayther et al., 1997) . However, our ®nding that most cancer-associated mutations in Ab are functionally defective argues against this idea. If the mutations had occurred randomly throughout the Ab subunit and if they would not provide a growth advantage, one would expect that a larger number of mutants that are not defective in B or C subunit binding had been found. Further support for the idea that Ab mutants play a role in growth control comes from the ®nding that the double mutant, L101P/V448A, is more defective in B and C subunit binding than each of the single mutants. This suggests that in the course of tumor development cells that acquired the second mutation had a selective growth advantage over cells with a single mutation. The results presented here and in a previous report (Ruediger et al., 2001) are consistent with the proposal that PP2A functions as a tumor suppressor and that mutations in Aa or Ab destroy this function by destroying or altering the binding of B or C subunits. Speci®cally, our data suggest that AaCB'a1 and AbCB''/PR72 are implicated in growth control. However, a direct demonstration that PP2A is a tumor suppressor is still missing.
Materials and methods
Mutants of PP2A-Ab
Glen Evans generously supplied us with a human Ab cDNA clone, pcDNA3.1-Ab. Sequencing revealed ®ve nucleotide deviations, two causing amino acid changes when compared to the published wild-type Ab sequence. These two positions were corrected by site-directed mutagenesis using Promega's Gene Editor kit. In order to construct C-terminally EEtagged Ab, an NheI site was introduced between the last and the stop codon of Ab in plasmid pcDNA3.1, which has a NotI site in its polylinker downstream of the Ab insert. The NheI ± NotI piece was excised and replaced with an in vitro synthesized piece of DNA that encodes, N-to C-terminally, an NheI site, sequence coding for the EE tag (EEEEYMPME), a stop codon, a BspEI site for screening, and a NotI site. In another round of mutagenesis, the NheI site was removed again so that the Ab wild-type sequence is immediately followed by the EE tag, as is the case in control plasmid pcDNA3-Aa EE (Ruediger et al., 1999) . Finally, the BamHI ± XhoI Ab EE insert of pcDNA3.1 was moved into pcDNA3 to yield pcDNA3-Ab EE . This plasmid was used to generate the mutants described by Wang et al. (1998) . All mutations were con®rmed by sequencing (MacConnell Research Corporation, San Diego, and UCSD Cancer Center Sequencing Facility). pcDNA3-Ab EE was sequenced repeatedly to ensure that the results showing that wild-type Ab does not bind to Ba and B'a1 were actually based on the analysis of real wild-type Ab. The wild-type Ab sequence used here conforms to our own unpublished human Ab sequence, to the sequence with accession number AF087438 cited by Wang et al. (1998) , and to the human Ab sequence published by Brian Hemmings and collaborators (Hemmings et al., 1990) , except that the latter has a threonine at position 178 instead of an isoleucine. This could be due to polymorphism. Pig (Hemmings et al., 1990) and Xenopus (Bosch et al., 1995) have an isoleucine at position 178. It is also worth mentioning that the equivalent position to isoleucine 178 in Ab is a leucine 166 in Aa. Mutation of this leucine to glutamic acid has no eect on B subunit binding of Aa (Ruediger et al., 1999) , indicating that this position is also not critical for B subunit binding of Ab.
In vitro translation, complex formation, immunoprecipitation and quantitation
To analyse B subunit binding to Ab subunit wild-type and mutants, Ab and B subunits were synthesized separately using Promega's TNT T7 Quick system and L-[ 35 S]methionine (437 TBq/mmol) (Amersham), followed by complex formation and immunoprecipitation with anti-EE antibodies as described previously (Ruediger et al., 1999) . To analyse for C subunit binding to Ab subunit wild-type and mutants, Ab subunits were synthesized using Promega's TNT T7 Quick system and L-[ 35 S]methionine (437 TBq/mmol) (Amersham), followed by complex formation and immunoprecipitation with antibody against the C subunit C-terminal peptide KL (KVTRRTPDYFL), as described (Ruediger et al., 1992) . The immunoprecipitates were analysed by SDS ± PAGE and phosphorimaging as described (Ruediger et al., 1999) .
